Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 5, 2008 - Issue 1
Submit an article Journal homepage
157
Views
18
CrossRef citations to date
0
Altmetric
Review

Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy

Michael J Brumlik Assistant Professor of Medicine University of Texas Health Sciences Center at San Antonio, San Antonio Cancer Institute, 2040 Babcock Road, Suite 201, San Antonio, TX 78229, USA +1 210 562 5276; +1 210 562 5292; [email protected]
, PhD,
Benjamin J Daniel Instructor of Medicine University of Texas Health Sciences Center at San Antonio, San Antonio Cancer Institute, 2040 Babcock Road, Suite 201, San Antonio, TX 78229, USA
, PhD,
Reinhard Waehler Postdoctoral Fellow The University of Alabama at Birmingham, Division of Human Gene Therapy, 901 19th Street South, Birmingham, AL 35294, USA
, Phd,
David T Curiel Professor of Medicine, Director of the Division of Human Gene Therapy, Director of the Gene Therapy Center The University of Alabama at Birmingham, Division of Human Gene Therapy, 901 19th Street South, Birmingham, AL 35294, USA
, MD PhD,
Francis J Giles Professor of Medicine, Chief of the Division of Hematology and Medical Oncology, Director of Experimental Therapeutics, San Antonio Cancer Institute, University of Texas Health Sciences Center at San Antonio, 2040 Babcock Road, Suite 201, San Antonio, TX 78229 Director, Institute for Drug Development, Cancer Therapy & Research Center, 7373 Wurzbach Road, San Antonio 78229, USA
, MB MD FRCPI FRCPath &
Tyler J Curiel
, MD MPH
Pages 87-103 | Published online: 21 Dec 2007

Bibliography

  • Gensini GF, Conti AA, Lippi D. The contributions of Paul Ehrlich to infectious disease. J Infect 2007;54(3):221-4
  • Silverstein AM. The collected papers of Paul Ehrlich: why was volume 4 never published? Bull Hist Med 2002;76(2):335-9
  • Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6(7):559-5
  • Kreitman RJ, Pastan I. Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 2006;7(10):1301-11
  • Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-7
  • Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997;3(12):1362-8
  • Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol 2003;3(4):386-90
  • Kratz F, Abu Ajaj K, Warnecke A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin Investig Drugs 2007;16(7):1037-58
  • Hursey M, Newton DL, Hansen HJ, et al. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics. Leuk Lymphoma 2002;43(5):953-9
  • De Lorenzo C, Nigro A, Piccoli R, D'Alessio G. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. FEBS Lett 2002;516(1-3):208-12
  • Song E, Zhu P, Lee Sk, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23(6):709-17
  • Chaudhary VK, Queen C, Junghans RP, et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989;339(6223):394-7
  • O'neil KT, Hoess RH, Jackson SA, et al. Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library. Proteins 1992;14(4):509-15
  • Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007;8:573-87
  • Akhtar S, Maghfoor I. Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med 2002;346(23):1830-1
  • Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99(10):3554-61
  • Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006;56(4):226-43
  • Ghetie MA, Richardson J, Tucker T, et al. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res 1991;51(21):5876-80
  • Schnell R, Vitetta E, Schindler J, et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 2000;14(1):129-35
  • Engert A, Diehl V, Schnell R, et al. A Phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997;89(2):403-10
  • Amlot PL, Stone MJ, Cunningham D, et al. A Phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993;82(9):2624-33
  • Sausville EA, Headlee D, Stetler-stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a Phase I study. Blood 1995;85(12):3457-65
  • Smallshaw JE, Ghetie V, Rizo J, et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol 2003;21(4):387-91
  • Chiron MF, Fryling CM, Fitzgerald DJ. Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem 1994;269(27):18167-76
  • Mckee ML, Fitzgerald DJ. Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story. Biochemistry 1999;38(50):16507-13
  • Theuer CP, Buchner J, Fitzgerald D, Pastan I. The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. Proc Natl Acad Sci USA 1993;90(16):7774-8
  • Theuer C, Kasturi S, Pastan I. Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes. Biochemistry 1994;33(19):5894-900
  • Keppler-Hafkemeyer A, Kreitman RJ, Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int J Cancer 2000;87(1):86-94
  • Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345(4):241-47
  • Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23(27):6719-29
  • Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002;8(4):995-1002
  • Bregni M, Siena S, Formosa A, et al. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells. Blood 1989;73(3):753-62
  • Dijoseph JF, Armellino DC, Boghaert ER. et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004;103(5):1807-14
  • Dijoseph JF, Goad ME, Dougher MM, et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin. Cancer Res. 2004;10(24):8620-9
  • Dijoseph JF, Dougher MM, Kalyandrug LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006;12(1):242-49
  • Multani PS, O'day S, Nadler LM, Grossbard ML. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 1998;4(11):2599-604
  • Lambert JM, McIntyre G, Gauthier MN, et al. The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry 1991;30(13):3234-47
  • Messmann RA, Vitetta ES, Headlee D, et al. A Phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000;6(4):1302-13
  • Ek O, Gaynon P, Zeren T, et al. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase. Leuk Lymphoma 1998;31(1-2):143-9
  • Schnell R, Borchmann P, Staak JO, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003;14(5):729-36
  • Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18(8):1622-36
  • Kreitman RJ, Wilson WH, Robbins D, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999;94(10):3340-48
  • Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 1998;58(5):968-75
  • Onda M, Kreitman RJ, Vasmatzis G, Lee B, Pastan I. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol 1999;163(11):6072-7
  • Kreitman RJ. Confirmation and prevention of targeted toxicity by a recombinant fusion toxin. Mol Cancer Ther 2004;3(12):1691-2
  • Schnell R, Staak O, Borchmann P, et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002;8(6):1779-86
  • Winkler U, Barth S, Schnell R, Diehl V, Engert A. The emerging role of immunotoxins in leukemia and lymphoma. Ann Oncol 1997;8(Suppl. 1):139-46
  • O'Toole JE, Esseltine D, Lynch TJ, Lambert JM, Grossbard ML. Clinical trials with blocked ricin immunotoxins. Curr Top Microbiol Immunol 1998;234:35-56
  • Giles FJ. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Rev Anticancer Ther 2002;2(6):630-40
  • Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003;98(10):2095-104
  • Law CL, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 2004;10(23):7842-51
  • Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281(15):10540-7
  • Law CL, Gordon KA, Toki BE, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 2006;66(4):2328-37
  • Ma D, Hopf CE, Malewicz AD, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006;12(8):2591-6
  • Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther 2006;5(6):1474-82
  • Bhaskar V, Law DA, Ibsen E, et al. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res 2003;63(19):6387-94
  • Tse KF, Jeffers M, Pollack VA, et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006;12(4):1373-82
  • Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21(7):778-84
  • Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a Phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21(2):211-22
  • Ricart AD, Tolcher AW. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract 2007;4(4):245-55
  • Tassone P, Gozzini A, Goldmacher V, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2(′)-deacetyl-N2′-(3-mercapto- 1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 2004;64(13):4629-36
  • Tassone P, Goldmacher VS, Neri P, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004;104(12):3688-96
  • Pai-scherf LH, Villa J, Pearson D, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin. Cancer Res 1999;5(9):2311-15
  • Azemar M, Djahansouzi S, Jager E, et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 2003;82(3):155-64
  • Von Minckwitz G, Harder S, Hovelmann S, et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 2005;7(5):R617-26
  • Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996;2(3):350-3
  • Posey JA, Khazaeli MB, Bookman MA, et al. A Phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002;8(10):3092-9
  • Chowdhury PS, Pastan I. Analysis of cloned Fvs from a phage display library indicates that DNA immunization can mimic antibody response generated by cell immunizations. J Immunol Methods 1999;231(1-2):83-91
  • Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10(12 Part 1):3937-42
  • Zalcberg JR, Pietersz G, Toohey B, et al. A Phase I/II study of the intralesional injection of ricin-monoclonal antibody conjugates in patients with hepatic metastases. Eur J Cancer 1994;30A(9):1227-31
  • Byers VS, Rodvien R, Grant K, et al. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res 1989;49(21):6153-60
  • Lorusso PM, Lomen PL, Redman BG, et al. Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer. Am J Clin Oncol 1995;18(4):307-12
  • Weiner LM, O'Dwyer J, Kitson J, et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res 1989;49(14):4062-7
  • Gould BJ, Borowitz MJ, Groves ES, et al. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst 1989;81(10):775-81
  • Lynch TJ Jr, Lambert JM, Coral F, et al. Immunotoxin therapy of small-cell lung cancer: a Phase I study of N901-blocked ricin. J Clin Oncol 1997;15(2):723-34
  • Fidias P, Grossbard M, Lynch TJ Jr. A Phase II study of the immunotoxin N901-blocked ricin in small-cell lung cancer. Clin Lung Cancer 2002;3(3):219-22
  • Pai LH, Bookman MA, Ozols RF, et al. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 1991;9(12):2095-103
  • McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294(5546):1537-40
  • Mcdevitt MR, Scheinberg DA. Ac-225 and her daughters: the many faces of Shiva. Cell Death Differ 2002;9(6):593-4
  • Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002;8(5):1004-13
  • Williams DP, Wen Z, Watson RS, et al. Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. J Biol Chem 1990;265(33):20673-77
  • Phan LD, Perentesis JP, Bodley JW. Saccharomyces cerevisiae elongation factor 2. Mutagenesis of the histidine precursor of diphthamide yields a functional protein that is resistant to diphtheria toxin. J Biol Chem 1993;268(12):8665-8
  • Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007;67
  • Diab A, Cohen Ad, Alpdogan O, Perales MA. IL-15: targeting CD8+ T cells for immunotherapy. Cytotherapy 2005;7(1):23-35
  • Frankel AE, Ramage J, Kiser M, et al. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng 2000;13(8):575-81
  • Urieto JO, Liu T, Black JH, et al. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for Phase I clinical trials. Protein Expr Purif 2004;33(1):123-33
  • Rand RW, Kreitman RJ, Patronas N, et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6(6):2157-65
  • Parney IF, Kunwar S, Mcdermott M, et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 2005;102(2):267-75
  • Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox intraparenchymal study group. J Clin Oncol 2007;25(7):837-44
  • Goldberg MR, Heimbrook DC, Russo P, et al. Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res 1995;1(1):57-61
  • Sampson JH, Reardon DA, Friedman AH, et al. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neurooncology 2005;7(1):90-6
  • Foss FM. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000;1(2):110-16; discussion 117
  • Lemaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998;91(2):399-405
  • Olsen E, Duvic M, Frankel A, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19(2):376-88
  • Mcginnis KS, Shapiro M, Junkins-hopkins JM, et al. Denileukin diftitox for the treatment of panniculitic lymphoma. Arch Dermatol 2002;138(6):740-2
  • Frankel AE, Fleming DR, Hall PD, et al. A Phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 2003;9(10 Part 1):3555-61
  • Dang NH, Hagemeister FB, Pro B, et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2004;22(20):4095-102
  • Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. Leuk Res 2002;26(12):1077-83
  • Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 2002;100(4):1399-403
  • Foss F, Demierre MF, Divenuti G. A Phase-I trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005;106(2):454-7
  • Robb RJ, Greene WC, Rusk CM. Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. J Exp Med 1984;160(4):1126-46
  • Ellery JM, Nicholls PJ. Possible mechanism for the α subunit of the interleukin-2 receptor (CD25) to influence interleukin-2 receptor signal transduction. Immunol Cell Biol 2002;80(4):351-7
  • Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6(4):295-307
  • Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117(5):1167-74
  • Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005;54(6):369-77
  • Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115(12):3623-33
  • Mahnke K, Schonfeld K, Fondel S, et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007;120(12):2723-33
  • Attia P, Powell DJ Jr, Maker AV, et al. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother 1997 2006;29(2):208-14
  • Roth DB. Restraining the V(D)J recombinase. Nat Rev Immunol 2003;3(8):656-66
  • Krangel MS. Gene segment selection in V(D)J recombination: accessibility and beyond. Nat. Immunol. 20034(7);624-30
  • Palmer E. The T-cell antigen receptor: a logical response to an unknown ligand. J Recept Signal Transduct Res 2006;26(5-6):367-78
  • Curiel TJ, Morris C, Brumlik M, et al. Peptides identified through phage display direct immunogenic antigen to dendritic cells. J Immunol 2004;172(12):7425-31
  • Berek JS. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther 2004;4(7):1159-65
  • Ehlen TG, Hoskins PJ, Miller D, et al. A pilot Phase II study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 2005;15(6):1023-34
  • Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2007;29(1):53-71
  • Reynolds PN, Zinn KR, Gavrilyuk VD, et al. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2000;2(6):562-78
  • Reynolds PN, Nicklin SA, Kaliberova L, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001;19(9):838-42
  • Ohno K, Sawai K, Iijima Y, Levin B, Meruelo D. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol 1997;15(8):763-7
  • Gigout L, Rebollo P, Clement N, et al. Altering AAV tropism with mosaic viral capsids. Mol Ther 2005;11(6):856-65
  • Korokhov N, Mikheeva G, Krendelshchikov A, et al. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J. Virol. (2003) 77(24);12931-12940
  • Tai CK, Logg CR, Park JM, et al. Antibody-mediated targeting of replication-competent retroviral vectors. Hum Gene Ther 2003;14(8):789-802
  • Morizono K, Xie Y, Ringpis GE, et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005;11(3):346-52
  • Chowdhury S, Chester KA, Bridgewater J, Collins MK, Martin F. Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors. Mol Ther 2004;9(1):85-92
  • Hedley SJ, Auf Der Maur A, Hohn S, et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther 2006;13(1):88-94
  • Brinkmann U, Pai Lh, Fitzgerald Dj, Willingham M, Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA 1991;88(19):8616-20
  • Li HJ, Everts M, Pereboeva L et al. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res 2007;67(11):5354-61
  • Pereboev AV, Nagle JM, Shakhmatov MA, et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther 2004;9(5):712-20
  • Korokhov N, De Gruijl TD, Aldrich WA, et al. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol Ther 2005;4(3):289-94
  • Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2(3):457-70
  • Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006;107(6):2409-14
  • Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23(9):1137-46
  • Tsutsumi Y, Onda M, Nagata S, et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 2000;97(15):8548-53
  • Foran JM. Antibody-based therapy of non-Hodgkin's lymphoma. Best Pract Res 2002;15(3):449-65
  • Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted α-particle radiotherapy. Curr Pharm Des 2000;6(14):1433-55
  • Jurcic JG, Larson SM, Sgouros G, et al. Targeted α particle immunotherapy for myeloid leukemia. Blood 2002;100(4):1233-9
  • Tsimberidou AM, Giles FJ, Estey E, et al. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 2006;132(4):398-409
  • Stone MJ, Sausville EA, Fay JW, et al. A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996;88(4):1188-97
  • Gibson AD. Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma 2002;3(1):18-19
  • Gibson AD. Updated results of a Phase III trial comparing ibritumomab tiuxetan with rituximab in previously treated patients with non-Hodgkin's lymphoma. Clin Lymphoma 2002;3(2):87-9
  • Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005;14(9):2436-46
  • Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004;10(23):7792-8
  • Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177-lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23(21):4591-601
  • Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2006;28(3):185-206
  • Ozguroglu M, Turna H. Rituximab-induced tumor progression: does it really happen? Med Oncol 2004;21(2):205-6
  • Izumi Y, Xu L, Di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002;416(6878):279-80
  • Sharkey RM, Brenner A, Burton J, et al. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 2003;44(12):2000-18
  • Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21(16):3051-9
  • Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20(10):2453-63

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.